iiinova — where your digital self keeps evolving

Susan G. Komen @susangkomen.bsky.social · 01/10/2026

Let's be honest. Breast cancer isn't over. This October, take action. Don't Fail the Girls. Komen.org #DontFailtheGirls

Susan G. Komen @susangkomen.bsky.social · 30/09/2026

Do you have dense breasts? Is it common? What does it even mean? Don't worry - we're breaking it all down today for World Dense Breast Day. Learn more: bit.ly/4rIHCgd

010

Susan G. Komen @susangkomen.bsky.social · 22/09/2026

In the phase 2 EVOLVE-BDT clinical trial, researchers are matching people with advanced or metastatic breast cancer to personalized treatments based on their tumor’s unique genetic markers. Learn more: bit.ly/4cZM84g

000

Susan G. Komen @susangkomen.bsky.social · 21/09/2026

Imlunestrant (Inluriyo) with abemaciclib (Verzenio), a CDK4/6 inhibitor, is now approved in the U.S. for hormone receptor-positive, HER2-negative MBC with an ESR1 mutation. Backed by results from the EMBER-3 trial. Learn more through our Breast Cancer Breakthrough series: bit.ly/4rq0H7i

000

Susan G. Komen @susangkomen.bsky.social · 15/09/2026

As Hispanic Heritage Month starts today, we want to highlight breast health and resources for Hispanic and Latina women. Breast cancer is the most common cancer and leading cause of cancer death among Hispanic and Latina women. Visit komen.org/espanol for more educational information in Spanish.

000

Susan G. Komen @susangkomen.bsky.social · 27/08/2026

NEW Breast Cancer Breakthroughs today! Curious about the use of artificial intelligence (AI) in breast cancer care? Tune in as Komen experts discuss how AI is being used, its potential for the future and what patients should know as they navigate today’s AI-driven landscape. bit.ly/3SEdrtV

000

Susan G. Komen @susangkomen.bsky.social · 27/08/2026

The PAM pathway can be confusing & riddled with acronyms, but we break down what it means in breast cancer care, the role of testing and different ways it can be targeted in treatment. Read our blog “Decoding the PAM Pathway in Metastatic Breast Cancer”: bit.ly/3SrKHVd

000

Susan G. Komen @susangkomen.bsky.social · 24/08/2026

Join us on Tuesday, September 1, 2026, from 2-3pm CT for a clear, candid webinar on how AI may impact treatment decisions, insurance coverage and patient advocacy – and what you need to know about its benefits, risks and limitations. Register here: bit.ly/4y2x5in

000

Susan G. Komen @susangkomen.bsky.social · 21/08/2026

All breast cancers are tested for HER2 status. This information is part of breast staging and helps guide treatment. Visit komen.org to learn more.

000

Susan G. Komen @susangkomen.bsky.social · 18/08/2026

What if technology could help connect people with breast cancer to clinical trials? AI is opening new conversations about clinical trial matching, accessibility and health equity in breast cancer research. Learn more: bit.ly/467DoVE

001

Susan G. Komen @susangkomen.bsky.social · 18/08/2026

We're proud to support today's scientists and clinicians who are playing key roles in breakthrough research to prevent and cure breast cancer. In honor of World Breast Cancer Research Day, learn more about the promising science that is transforming patient outcomes: bit.ly/4wriexd

000

Susan G. Komen @susangkomen.bsky.social · 17/08/2026

Want to make a difference in your community? Volunteer at a Race for the Cure or MORE THAN PINK Walk in your area to support our mission create a future where nobody dies from breast cancer. Find an event near you: bit.ly/45pEjAF

000

Susan G. Komen @susangkomen.bsky.social · 14/08/2026

Our patient navigation program takes a multifaceted approach to address inequities and barriers in the healthcare system. We connect patients to resources and support at every step of their breast care journey. Join our program today: bit.ly/3AoclGe

000

Susan G. Komen @susangkomen.bsky.social · 13/08/2026

A new study from Komen Scientific Advisory Board member Adrian Lee and former Komen Scholar Steffi Oesterreich identified possible reasons hormone receptor-positive breast cancer becomes more common with age using tumor samples from the Komen Tissue Bank. Read the full study: bit.ly/4pYmGl1

000

Susan G. Komen @susangkomen.bsky.social · 06/08/2026

We're here for you 🩷💙 Whether you're newly diagnosed or supporting a loved one living with breast cancer, our patient navigators are available to support you. Call 1-877 GO KOMEN or email helpline@komen.org to get started.

000

Susan G. Komen @susangkomen.bsky.social · 23/07/2026

We're coming into the homestretch of our Fundraising Challenge, but there's still time to earn some Komen swag! Register and raise $31 by July 31 for a Race or Walk to earn an exclusive Komen keychain. Visit komen.org for the full terms and conditions.

000

Susan G. Komen @susangkomen.bsky.social · 22/07/2026

Dr. Kimberly Sabelko, Komen's VP of Scientific Strategy and Programs, chats with @oncodaily.bsky.social to discuss our $15.4 million investment in breast cancer research, why MBC is the main focus & how AI is playing a role in breast cancer research. Watch the full interview: bit.ly/4yDNX02

000

Susan G. Komen @susangkomen.bsky.social · 21/07/2026

A big Congressional victory for the breast cancer community! The Breast Cancer Education and Awareness Requires Learning Young (EARLY) Act Reauthorization of 2025 & the Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act passed on the House floor!

111

Susan G. Komen @susangkomen.bsky.social · 20/07/2026

The OASIS-4 clinical trial is studying elinzanetant, a new non-hormonal medication, for women who have HR+ breast cancer, or are at high risk for it, and are dealing with hot flashes and night sweats caused by hormone therapy.

100

Susan G. Komen @susangkomen.bsky.social · 17/07/2026

GLP-1s are making headlines and breast cancer researchers are paying close attention. A new CURE article featuring insights from Komen staff explores what we know so far, what questions remain and why any decision about GLP-1s should be guided by an oncology care team. bit.ly/4fFEJss

bit.ly

GLP-1s: Weight Loss and Survival in Breast Cancer Recovery | CURE

ASCO 2026 findings and patient stories show how GLP-1 drugs improve metabolic health and potentially transform breast cancer survivorship.

010

Susan G. Komen @susangkomen.bsky.social · 02/07/2026

Hispanic and Latina women are often diagnosed with later-stage breast cancers than white women, possibly due to delays in follow-up care after an abnormal screening mammogram. It's important to know your risk factors and advocate for yourself. Visit komen.org to learn more.

020

Susan G. Komen @susangkomen.bsky.social · 30/06/2026

Chemo brain isn’t random. It’s not “just in your head” -- Estrogen changes and treatment can affect how your brain communicates. Learn the biology behind brain fog in our latest Under the Microscope video. Watch the full episode: youtu.be/desV6bWFdyY

000

Susan G. Komen @susangkomen.bsky.social · 29/06/2026

Cancer clinical trial enrollment by adults in the U.S. is less than 5%. Breast cancer clinical trials study prevention, new screening tests and treatment options, as well as quality of life issues. Learn more about clinical trials at komen.org or email clinicaltrialinfo@komen.org.

000

Susan G. Komen @susangkomen.bsky.social · 25/06/2026

We're proud to have supported investigators who contributed to Phase III clinical trials that led to the latest expanded FDA approval for the use of each drug. You can learn all about these clinical trial results through our Breast Cancer Breakthroughs Series: bit.ly/4amC5EZ

000

Susan G. Komen @susangkomen.bsky.social · 25/06/2026

Many of today’s most significant advances in breast cancer treatment began as bold, early-stage concepts. We're proud to support innovative research that leverages AI, advanced technologies & new therapies to improve patient outcomes. Learn more about our 2026 Research Grants bit.ly/4wriexd

000

Susan G. Komen @susangkomen.bsky.social · 24/06/2026

Through clinical trials, researchers are uncovering smarter therapies that help patients live longer, feel better and hold onto the ultimate hope: a future without breast cancer. Learn more about the top breast cancer clinical trials featured at @ascocancer.bsky.social: bit.ly/4oHaCDM

000

Susan G. Komen @susangkomen.bsky.social · 24/06/2026

The cures are closer than ever. We’re pursuing the right data, the right questions and the treatments to make it possible. That's why today, we're excited to announce this year's $15.4 million investement in research and it's all thanks to your support!

komen.org

Komen’s Investment in the Future of Breast Cancer Research

Komen is investing in the future of breast cancer research, awarding $15.4 million to researchers working on accelerating breakthroughs.

100

Susan G. Komen @susangkomen.bsky.social · 21/06/2026

Many men have been where you are today. Social support is important after a breast cancer diagnosis. The Komen Patient Care Center can help you find a support group for you and your loved ones, or resources in your area. Call 1-877-GO KOMEN or email helpline@komen.org. We're here for you.

010

Susan G. Komen @susangkomen.bsky.social · 18/06/2026

Tune in to our upcoming episode to learn what's new in imaging for MBC. Bring your questions ready - it's a live Q&A! Dr. David Mankoff will share updated imaging practices for ER+ MBC and new data from a national clinical trial on FDG PET/CT for bone metastases. Register: bit.ly/4vebmTo

000

Susan G. Komen @susangkomen.bsky.social · 17/06/2026

Let’s talk about male breast cancer. Yes, it happens! Jake Messier is joined by Bret Miller and Richard Loud to talk about how they were initially diagnosed, their treatment plan, and resources that have helped them. Watch our premiere Men’s Health Month episode now: youtu.be/HgTyPTCT3HI

000

Susan G. Komen @susangkomen.bsky.social · 04/06/2026

Men who get breast cancer are more likely to have an inherited gene mutation than women who get breast cancer. For this reason, genetic testing for BRCA1 a&BRCA2 (BRCA1/2) gene mutations is recommended for all men diagnosed w/ breast cancer. Learn more about genetic testing: bit.ly/4amgGvv

000

Susan G. Komen @susangkomen.bsky.social · 03/06/2026

Thrilled to see many Komen-supported grantees & posters at #ASCO26. Each reflects scientific progress and the dedication of researchers improving outcomes for people impacted by breast cancer. Proud to support science, moving us closer to a world without breast cancer. @ascocancer.bsky.social

110

Susan G. Komen @susangkomen.bsky.social · 03/06/2026

The future of breast cancer care depends on continued groundbreaking discoveries, and there’s incredible work happening right now.

100

Susan G. Komen @susangkomen.bsky.social · 02/06/2026

🧬 Sara Hurvitz, MD presents VIKTORIA-1 at #ASCO26: In HR+/HER2- PIK3CA-mutant breast cancer after CDK4/6i, gedatolisib + fulvestrant (with or without palbociclib) doubled progression-free survival vs standard of care (11.1 vs 5.6 months). 🎯 @ascocancer.bsky.social

010

Susan G. Komen @susangkomen.bsky.social · 02/06/2026

🧬 Francois Bidard, MD, Ph.D. presents SERENA-6 at #ASCO26: Switching to camizestrant + CDK4/6i when ESR1 mutations emerge during first-line therapy improved outcomes through 2 lines of treatment in HR+/HER2- advanced breast cancer @ascocancer.bsky.social

010

Susan G. Komen @susangkomen.bsky.social · 02/06/2026

GLP-1 use is rising but what about #breastcancer risk? Long term safety matters. At #ASCO26, Elizabeth Susan McDonald, MD, PhD reported GLP-1 treatment was associated with lower BC incidence in women, but clinical trials are needed to confirm a true risk reduction effect. @ascocancer.bsky.social

020

Susan G. Komen @susangkomen.bsky.social · 02/06/2026

PANKU-Breast02 phase 3 trial: iza-bren vs chemo in pre-treated metastatic TNBC. 📊 Jiong Wu, MD, PhD reported that patients had improved overall survival & stayed progression-free longer with manageable side effects, suggesting iza-bren could become a new standard option. @ascocancer.bsky.social

010

Susan G. Komen @susangkomen.bsky.social · 02/06/2026

Can ADCs improve outcomes in pts who can't get immunotherapy? 🤔 At #ASCO26, David Cescon, MD, PhD shared new TROPION-Breast02 data: Dato-DXd helped pts go longer w/o progression & delayed need for further tx vs chemo, supporting it as a potential new 1L standard in mTNBC. @ascocancer.bsky.social

010

Susan G. Komen @susangkomen.bsky.social · 02/06/2026

🧬Dr. Kevin Kalinsky presents ASCENT-04 at #ASCO26: Starting on sacituzumab govitecan + pembro upfront led to better outcomes through 2 lines of treatment in PD-L1+ metastatic TNBC - even vs patients who eventually received SG later. @ascocancer.bsky.social

010

Susan G. Komen @susangkomen.bsky.social · 02/06/2026

ASCENT-03 tests sacituzumab govitecan (SG) vs chemo in 1L metastatic TNBC Dr. Sara Tolaney presented new data showing improved PFS after next line of treatment & subsequent therapies, supporting SG as a potential new standard of care for those not eligible for PD-L1 therapy. @ascocancer.bsky.social

010

Susan G. Komen @susangkomen.bsky.social · 01/06/2026

At #ASCO26, Komen grantee Sharon Giordano, the recipient of the Gianni Bonadonna Breast Cancer Award, shared insights on opportunities, challenges and lessons learned in breast cancer outcomes research 🏆 @ascocancer.bsky.social

010

Susan G. Komen @susangkomen.bsky.social · 30/05/2026

Phase 3 KEYNOTE-522 final results 👀💥 Javier Cortes, MD, PhD presents data from the trial evaluating pembrolizumab + chemo before surgery, followed by adjuvant pembrolizumab vs placebo. #ASCO26 @ascocancer.bsky.social

031

Susan G. Komen @susangkomen.bsky.social · 30/05/2026

Recurrence remains a challenge in HR+/HER2- early #breastcancer. Phase 3 lidERA trial previously showed improvement with giredestrant (oral SERD) vs standard hormone therapy 📈 Peter Schmid, MD, PhD presents results by menopausal status at #ASCO26 @ascocancer.bsky.social

031

Susan G. Komen @susangkomen.bsky.social · 30/05/2026

New biomarker insights from NATALEE trial presented by Stephen Chia, MD 📊 Baseline gene expression shows prognostic & predictive impact in HR+/HER2- early #breastcancer treated with adjuvant ribociclib + aromatase inhibitor #ASCO26 @ascocancer.bsky.social

041

Susan G. Komen @susangkomen.bsky.social · 30/05/2026

Can some people safely avoid chemo in higher-risk early breast cancer? 🤔 OPTIMA phase 3 tests a genomic-guided strategy vs standard of care in HR+/HER2- #breastcancer. Robert Stein, PhD presents first results at #ASCO26 @ascocancer.bsky.social

031

Susan G. Komen @susangkomen.bsky.social · 29/05/2026

Congratulations to past and present Komen grantees Nancy Davidson MD, Sharon Giordano MD, Charles Loprinzi MD and Jason Freeman for receiving awards at this year's #ASCO2026 !!!🎉 @ascocancer.bsky.social

010

Susan G. Komen @susangkomen.bsky.social · 29/05/2026

📢 Heading to #ASCO26? Visit us at booth 13000 in the Exhibit Hall 📆 May 30-June 1 from 9 am - 5 pm Connect with our team and learn more about our work in patient support, advocacy, research funding, education and resources for the breast cancer community. @ascocancer.bsky.social

000

Susan G. Komen @susangkomen.bsky.social · 27/05/2026

"Organizations like Susan G. Komen continue to highlight the importance of collaboration between healthcare providers, policymakers, community leaders, and advocacy groups to ensure lifesaving services remain available and accessible to all."

100

Susan G. Komen @susangkomen.bsky.social · 27/05/2026

Breast cancer surgery can come with lots of uncertainty and questions, especially when it comes to healing, recovery and dealing with things like scar tissue, swelling and surgical drains.

100

Susan G. Komen @susangkomen.bsky.social · 22/05/2026

New FDA approval: Trastuzumab deruxtecan (Enhertu) is now approved in the U.S. for HER2+ early breast cancer in both neoadjuvant (before surgery) and adjuvant (post-surgery) settings, based on DESTINY-Breast05 and DESTINY-Breast11 clinical trial results. Read more: bit.ly/4uU4KsT

000